[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-sclerosis-ms---relapsing-remitting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-sclerosis-ms---relapsing-remitting":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,74,111,141,177,196,231,260,285,311,340,369,402,425,460,481],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100615428","monthly-monitoring-of-plasma-nfl-in-treated-relapsing-remitting-multiple-sclerosis-to-detect-persistent-infraclinical-disease-activity-100615428",false,"NCT07292480","Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity","Monthly Monitoring of Plasma NfL in Treated RRMS to Detect Persistent Infraclinical Disease Activity","MoMo-NfL","Inclusion Criteria:\n\n* Patient with RRMS according to 2024 McDonald's criteria.\n* Less than 10 years from disease onset.\n* Active RRMS (EDA) observed during the last 24 months: relapse and\u002For NELs and\u002For CELs as compared to a previous MRI performed within 24 months (± 3 months).\n* Current MET (IFN, GA, TE, fumarates) for less than 24 months.\n* Standard MRI follow-up scan performed less than 90 days before inclusion.\n* Clinically stable disease for at least 30 days.\n* Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL.\n* For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial.\n* Patients able to adhere to the study visit schedule.\n* Patient must have signed and given the consent.\n* Patient affiliated or beneficiary of a health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman.\n* Patient unable to perform brain and\u002For spinal cord MRI scans.\n* Patient not willing to perform monthly blood punctures.\n* Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone).\n* Patient with a relapse within 6 months before inclusion.\n* Patient with CELs within 3 months before inclusion.\n* Patient with progressive MS.\n* Patient unable to sign the consent.\n* It is impossible to correctly inform the patient.\n* Patient already participating in therapeutic research or in an exclusion period. The exclusion period corresponds to five half-lives (t1\u002F2) of the experimental drug.\n* Patient under judicial protection, or is an adult under guardianship.\n* Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control for the duration of the trial.","ALL","18 Years","55 Years",{"count":21,"type":22},84,"ESTIMATED","INTERVENTIONAL",[25],"NA","Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2\u002FFLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response. However, some studies have suggested the deposition of gadolinium-based contrast agents in the basal ganglia and dentate nucleus of patients who underwent serial MRI acquisitions. Although significant clinical consequences of these deposits have not been demonstrated, further studies are required to better understand the potential long-term biological and clinical effects of gadolinium administration. To circumvent this potential risk, several recommendations suggested avoiding unnecessary use of gadolinium for follow-up scans. New sequences are also developed to replace gadolinium injection for the detection of active lesions. Moreover, MRI remains costly and time-consuming. In addition, systematic yearly MRI monitoring is not adapted to detect silent active lesions. This can delay identification of treatment failure and increase the risk of relapses and disability worsening, especially in the context of escalation therapy.\n\nTherefore, biological markers could allow more frequent analysis of disease activity and detect treatment failure earlier than classical clinical and MRI monitoring. Their use would greatly help clinicians to switch for high efficacy treatments (HET) and avoid potential relapses.\n\nMeasurement of a structural axonal protein, neurofilament, in serum or plasma has shown promise as a marker of neuroaxonal injury and a measure of treatment response. In MS, cerebrospinal fluid (CSF) neurofilament-light chain (NfL) is also increased and is positively associated with MRI lesion load and disability scores and is a marker of treatment response.\n\nWThe study authors hypothesize that monthly plasma neurofilament-light chain (pNfL) monitoring can sensitively highlight subclinical (radiological disease activity) RDA by performing early MRI scans to confirm EDA and lead to timely treatment escalation.\n\nThe main objective of this study is to compare the time to EDA in both arms (monthly pNfL monitoring vs. standard care with regular MRI scans), in patients with EDA.",[28],"Multiple Sclerosis (MS) - Relapsing-remitting",[30],"Biomarker","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":35},"2025-12-12",{"date":39,"type":22},"2030-12",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nīmes","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100642511","effects-of-low-load-blood-flow-restriction-exercise-on-rectus-femoris-muscle-morphology-in-individuals-with-relapsing-remitting-multiple-sclerosis-100642511","NCT07645937","Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis","Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis: A Three-Arm Randomized Controlled Trial","RRMS-BFR","Inclusion Criteria:\\* Age 18-65 years\n\n* Diagnosis of relapsing-remitting multiple sclerosis according to revised McDonald criteria\n* EDSS score between 2.5 and 3.5\n* Clinically stable disease\n* No relapse within the previous 3 months\n* No corticosteroid treatment within the previous 3 months\n* Ability to participate in exercise training\n* Written informed consent\n\nExclusion Criteria:\\* Deep vein thrombosis or pulmonary embolism history\n\n* Peripheral vascular disease\n* Uncontrolled hypertension\n* Severe cardiovascular disease\n* Pregnancy\n* Recent lower extremity surgery or injury\n* Musculoskeletal or neurological conditions interfering with exercise participation\n* Contraindications to blood flow restriction training\n* Participation in another structured exercise trial during the study period","65 Years",{"count":54,"type":22},30,[25],"Multiple sclerosis (MS) is a chronic neurological disease associated with reduced muscle strength, impaired mobility, increased fatigue, and deterioration in muscle morphology. Rectus femoris muscle atrophy and reduced muscle quality have been linked to functional limitations and decreased mobility in individuals with MS.\n\nBlood flow restriction (BFR) training is a rehabilitation strategy that combines low-load exercise with partial vascular occlusion, enabling muscular adaptations comparable to those achieved with higher exercise loads. Although BFR has demonstrated promising results in several clinical populations, evidence regarding its effects on muscle morphology in individuals with relapsing-remitting multiple sclerosis (RRMS) remains limited.\n\nThe purpose of this randomized controlled trial is to investigate the effects of low-load BFR exercise on rectus femoris muscle morphology in individuals with RRMS. Thirty participants with RRMS (EDSS 2.5-3.5) will be randomly assigned to one of three groups: a BFR exercise group, a sham-BFR exercise group, or an exercise-only control group. All participants will complete the same supervised exercise program twice weekly for eight weeks.\n\nThe primary outcome will be rectus femoris muscle thickness assessed by ultrasonography. Secondary outcomes will include rectus femoris echo intensity, knee extensor muscle strength, Timed 25-Foot Walk performance, Nine-Hole Peg Test performance, Symbol Digit Modalities Test scores, and Modified Fatigue Impact Scale scores.\n\nThis study aims to determine whether the addition of blood flow restriction to a standardized low-load exercise program results in superior morphological and functional adaptations compared with sham-BFR and exercise-only conditions in individuals with RRMS.",[28],[59,60,61,62,63],"Relapsing-Remitting Multiple Sclerosis","Blood Flow Restriction","BFR Training","Rectus Femoris","Muscle Morphology","NOT_YET_RECRUITING","2026-06-09",{"date":67,"type":35},"2026-06-12",{"date":69,"type":22},"2026-07-01",{"date":71,"type":22},"2027-04-01",{"name":73,"class":42},"Hanifi Bal",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100643835","acute-intermittent-hypoxia-combined-with-gait-training-in-multiple-sclerosis-100643835","NCT07631923","Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis","Acute Intermittent Hypoxia (AIH) Primed Myoelectric Interface Neurorehabilitation Training (MINT) for Gait Recovery in Multiple Sclerosis","MINT","Inclusion Criteria:\n\n* Diagnosis of clinically definite multiple sclerosis\n* Patient-Determined Disease Steps (PDDS) score between 3 and 6\n* Relapse-free for at least 6 months prior to enrollment\n* Age ≥ 18 years and ≤ 75 years\n* Resting oxygen saturation (SpO₂) ≥ 95% on room air\n* Systolic blood pressure between 85-140 mmHg and diastolic blood pressure between 55-90 mmHg\n* Modified Ashworth Scale (MAS) score ≤ 3 at the ankle and knee\n* Mini-Mental State Examination (MMSE) score ≥ 24\n* Ability to walk at least 10 meters with or without an assistive device\n* Ability to perform active ankle dorsiflexion and plantarflexion\n\nExclusion Criteria:\n\n* Uncontrolled hypertension or hypotension outside the required ranges\n* History of epilepsy or seizures\n* Uncontrolled pulmonary, cardiovascular, or orthopedic disease\n* Premorbid or ongoing major psychiatric illness (e.g., major depression, psychosis)\n* Other neurological disease (e.g., stroke, traumatic brain injury, peripheral neuropathy)\n* Illnesses with potential to cause brain injury\n* Frequent or severe unexplained headaches\n* Pregnancy\n* Implanted medical devices (e.g., pacemakers, intrathecal pumps, brain stimulators)","75 Years",{"count":84,"type":22},35,[25],"This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves gait in people with Multiple Sclerosis. The primary objectives are to evaluate changes in gait speed and endurance, with secondary objectives assessing spatiotemporal gait parameters, fatigue, and safety. Participants will receive AIH or sham priming followed by standardized treadmill and\u002For overground gait training, with outcome measures collected before and after the intervention across multiple sessions.",[88,28,89,90],"Multiple Sclerosis","Multiple Sclerosis (MS) Primary Progressive","Multiple Sclerosis (MS) Secondary Progressive",[92,93,94,95,96,97,98,99,100,101],"hypoxia","neuroplasticity","rehabilitation","gait","recovery","walking","walk","lower extremities","strength","AIH","2026-06-02",{"date":104,"type":35},"2026-06-08",{"date":106,"type":22},"2026-06-15",{"date":108,"type":22},"2028-06-01",{"name":110,"class":42},"Shirley Ryan AbilityLab",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100610082","phase-2-a-study-of-remibrutinib-using-mr-imaging-in-relapsing-or-progressive-ms-100610082","NCT07222956","A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS","An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)","RemiSeven","Inclusion Criteria:\n\nTo be eligible for the study, participants must meet the following eligibility criteria at the Screening visit:\n\n1. Written informed consent signed by participant.\n2. English-speaking.\n3. Male and female participants, 18-60 years of age inclusive.\n4. Established diagnosis of relapsing or progressive MS, as defined by the 2024 revision of McDonald Diagnostic Criteria (any form of MS). A diagnosis of MS must be confirmed at the time of the screening visit.\n5. Expanded Disability Status Score (EDSS) of 0 - 6.5, inclusive.\n6. Adequate vision and motor function to participate in assessment procedures.\n7. Females participating in the study must meet one the following criteria:\n\n   1. Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or\n   2. If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (β-hCG) test for pregnancy at screening and at each follow-up visit.\n8. Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose.\n9. Evidence of disease activity in the prior 12 months (at least one clinical relapse or one gadolinium enhancing lesion or new T2 lesion) or presence of disability worsening based clinician's assessment in the prior 12 months.\n10. Participants should be in reasonably good health and neurologically stable over the last 1 month (no MS relapse in this period).\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if any of the following exclusion criteria exist at the Screening Visit:\n\n1. Concurrent treatment with any disease modifying therapy for MS or systemic immunotherapy for other autoimmune or rheumatological disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease) according to study protocol.\n2. Ongoing substance abuse (drug or alcohol) or any other factor that may interfere with the participant's ability to cooperate and comply with study procedures.\n3. History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer) within the past 5 years regardless of treatment or metastasis status.\n4. History of liver disease or liver function abnormalities at baseline including Gilbert syndrome:\n\n   i. Acute or chronic liver disease ii. Cirrhosis iii. Any degree of hepatic impairment (i.e., mild, moderate, or severe) based on Child Pugh classification.\n\n   iv. Untreated hepatitis C or active hepatitis B infection v. Alcohol intake greater than 2 drinks\u002Fday for men and greater than 1 drink per day for women vi. Transaminases (i.e., AST or ALT) \\> 1.5x the upper limit of normal (ULN) vii. Total bilirubin \\>1.5 x ULN viii. Alkaline phosphatase \\> 2x ULN unless caused by non-liver related disorder or explained by a stable chronic liver disorder\n5. History of severe renal disease or creatinine level above 1.5 x upper limit normal.\n6. Pregnancy, planned or current.\n7. History of severe depression or suicidality.\n8. Hematological abnormalities at screening: hemoglobin \\\u003C 10 g\u002Fdl, platelets \\\u003C 100000\u002Fmm3, absolute lymphocyte count \\\u003C 800\u002Fmm3, white blood cells \\\u003C 3000\u002Fmm3, neutrophils \\\u003C 1500\u002Fmm3, B-cell count \\\u003C 50% lower limit of normal, total IgG or total IgM \\\u003C lower limit of normal.\n9. Active clinically significant bacterial, viral, parasitic, or fungal infections, in the judgement of the investigator.\n10. History of significant central nervous system disease (e.g. stroke, traumatic brain injury, myelopathy, progressive multifocal leukoencepahalopathy).\n11. History of splenectomy.\n12. History of active or latent tuberculosis with a positive QuantiFERON, at screening.\n13. Individuals with a known immunodeficiency syndrome, drug-induced immunodeficiency, hereditary immunodeficiency, or who test positive for Human immunodeficiency virus (HIV) antibody, at screening\n14. Clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, hematological, pulmonary, or gastrointestinal disorders that in the investigator's opinion would compromise the safety of the participant or interfere with the interpretation of the study results.\n15. History or current diagnosis of ECG abnormalities such as concomitant clinically significant cardiac arrhythmias, history of familial long QT syndrome, cardiac arrhythmias requiring anti-arrhythmic treatment with class Ia or III anti-arrhythmic drugs.\n16. Resting QT interval corrected by Fridericia's formula (QTcF) \\>450 msec (male) or \\>460 msec (female) prior to screening.\n17. Requirement for anticoagulant medication or use of dual anti-platelet therapy. Use of acetylsalicylic acid up to 100 mg\u002Fday or clopidogrel up to 75 mg\u002Fday, is permitted.\n18. Significant bleeding risk or history of clinically significant bleeding disorders.\n19. Use of gastric acid modifying agents, such as proton pump inhibitors or H2 antagonists.\n20. Use of any strong or moderate inhibitors of CYP3A4 (including clarithromycin, grapefruit, itraconazole, ketoconazole), or strong or moderate inducers of CYP3A4 (including carbamazepine, phenytoin, St John's Wort, primidone, modafinil). Use of BCRP or P-glycoprotein substrates. Use of any herbal\u002Fdietary supplements 8 weeks prior to first dose of study drug or during the study period. Concomitant medicines will be examined on a case-by-case basis against the Flockhart Table by study investigator, and if needed, the Medical Monitor, to determine allowability.\n21. Live vaccines within 6 weeks prior to screening or requirement to receive these vaccinations at any time during study treatment.\n22. Inability to complete MRI with contrast (claustrophobia, pacemaker, cochlear implant, metallic implants incompatible with MR, hypersensitivity to gadolinium-based contrast agent, or severe renal disease).\n23. Subjects who score \"yes\" to items 4 or 5 of the C-SSRS suicidal ideation or any of the items on C-SSRS suicidal behavior section at screening.\n24. Other factors that the Investigator determines would place the individual at risk for participation or interfere with interpretation of the results.","60 Years",{"count":121,"type":22},20,[123],"PHASE2","The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.",[28,90,89],[127,128,129,130],"multiple sclerosis","Relapsing","Progressive","Remibrutinib","2026-05-19",{"date":133,"type":35},"2026-05-20",{"date":135,"type":22},"2026-06-30",{"date":137,"type":22},"2030-12-30",{"name":139,"class":42},"Moein Amin",1,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":140},"100639518","healthy-eating-and-active-living-for-people-living-with-multiple-sclerosis-heal-ms-a-lifestyle-program-for-people-with-multiple-sclerosis-100639518","NCT07589062","Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis","HEAL MS: A Culturally Adapted Lifestyle Medicine Intervention Targeting Metabolic and Immune Dysregulation in Multiple Sclerosis Using Multi-Omics Profiling","HEAL-MS","Inclusion Criteria:\n\n* Confirmed MS diagnosis (McDonald criteria)\n* EDSS score ≤ 6.5 (i.e., ambulatory with or without assistance)\n* Stable disease-modifying therapy for ≥ 3 months\n* Age 18-50\n* Proficiency in English or Arabic\n* Clearance to participate in a structured exercise program\n* Ability to walk, sit and stand independently, and perform light-to-moderate movement patterns, even with modifications\n* Ability and digital literacy to interact with the bilingual HEAL MS mobile app and\n* Access to a computer for participation in online sessions\n\nExclusion Criteria:\n\n* Significant cognitive impairment affecting app use and comprehension of the intervention\n* MS relapse within the past 3 months\n* Pregnancy or planned pregnancy\n* Unmanaged psychiatric disorders\n* Other immune-related or chronic inflammatory or metabolic diseases\n* Concurrent enrollment in another lifestyle intervention","50 Years",{"count":54,"type":22},[25],"The goal of this clinical trial is to learn whether a structured lifestyle program can improve health and wellbeing in people living with multiple sclerosis (MS). The program focuses on four areas: nutrition, physical activity, sleep, and stress management. The study will also examine how lifestyle changes affect biological markers related to inflammation, metabolism, and immune function.\n\nThe main questions the study aims to answer are:\n\nCan a 12-week lifestyle program improve fatigue, physical function, sleep, and quality of life in people with MS? Do lifestyle changes influence biological markers related to inflammation, metabolism, and mitochondrial function?\n\nParticipants will first complete a 12-week observation period to measure their usual lifestyle and health. After this, they will take part in the 12-week HEAL MS lifestyle program.\n\nParticipants will:\n\nAttend four assessment visits at Yas Clinic (baseline, before the intervention, after the intervention, and three months later) Participate in two supervised online exercise sessions per week during the 12-week program Follow a structured nutrition plan, with meals provided during the first two weeks Use a mobile application to log daily habits related to exercise, nutrition, sleep, and stress Complete questionnaires and physical tests and provide blood, saliva, and stool samples during assessment visits\n\nResearchers will analyze these data to understand whether lifestyle interventions can support symptom management and overall health in people living with MS.",[28,88],[88,155,156,157,158,159,160,161,162,163,164,165,166,167],"Lifestyle Medicine","Exercise Intervention","Lifestyle Intervention","Anti-Inflammatory Diet","Multiomics","Proteomics","Metabolomics","Mitochondrial Dysfunction","Digital Health","Behavioral Change","Fatigue","Neuroinflammation","Lifestyle Diet","2026-05-08",{"date":170,"type":35},"2026-05-15",{"date":172,"type":22},"2026-04-15",{"date":174,"type":22},"2027-11-15",{"name":176,"class":42},"New York University Abu Dhabi",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":140},"100582563","exploration-of-novel-imaging-biomarkers-on-oct-for-ublituximab-treatment-response-in-multiple-sclerosis-100582563","NCT06864936","Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis","Inclusion Criteria:\n\nFor Ublituximab Group:\n\n1. Ages 18-65\n2. A diagnosis of relapsing MS (to include relapsing-remitting MS and active secondary progressive MS) according to 2017 Revised McDonald Criteria.\n3. A recent referral for initiation of ublituximab for treatment of MS by the patient's treating physician.\n\nFor Comparison Group:\n\n1. Ages 18 - 65\n2. A diagnosis of relapsing-remitting MS according to 2017 Revised McDonald Criteria.\n3. Currently on a stable dose of disease modifying treatment for MS with no plans for alternative therapy for the following year.\n\nExclusion Criteria:\n\nFor Ublituximab Group:\n\n1. Known eye disease that may, in the opinion of the screening ophthalmologist, preclude proper analysis of data in this study. This includes, but is not limited to diabetic retinopathy, macular degeneration, and glaucoma.\n2. Treatment with any B-cell depleting disease modifying therapy for MS (i.e. rituximab, ocrelizumab, ofatumumab, ublituximab, etc.) within the past 12 months.\n3. History of life-threatening infusion reaction on ublituximab or prior anti-CD20 therapy\n4. Any chronic or active infection that would preclude anti-CD20 therapy. This may include but is not limited to active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests, tuberculosis, and human immunodeficiency virus (HIV).\n5. Receipt of any live of live-attenuated vaccines within 4 weeks prior to first ublituximab administration\n\nFor Comparison Group:\n\n1. Known eye disease that may, in the opinion of the screening ophthalmologist, preclude proper analysis of data in this study. This includes, but is not limited to diabetic retinopathy, macular degeneration, and glaucoma.\n2. Treatment with any B-cell depleting disease modifying therapy (i.e. rituximab, ocrelizumab, ofatumumab, ublituximab, etc.) within the past 12 months, or plans to initiate such a therapy in the following year.",{"count":54,"type":22},[25],"The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. This study will evaluate the efficacy of ublituximab to modulate MS pathology in a new manner. In order to assess this new biomarker, a specialized optical coherence tomography (OCT) scan will be performed at enrollment into the study and at 2 other timepoints throughout the study.\n\nSubjects asked to take part in this study should have been diagnosed with relapsing multiple sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication for the treatment of their MS.\n\nWe plan to enroll 30 patients into this study. Fifteen (15) patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are being initiated on B-cell depletion therapy by their treating physician at the University of Maryland Center for MS Treatment and Research will be offered enrollment into this study. Additionally, 15 age\u002Fsex matched patients with stable RRMS who are not undergoing any change in treatment and are not currently on B-cell depleting therapies will be enrolled as control subjects.",[28],"2026-04-29",{"date":189,"type":35},"2026-05-06",{"date":191,"type":22},"2026-05-01",{"date":193,"type":22},"2028-01-30",{"name":195,"class":42},"University of Maryland, Baltimore",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":140},"100610625","combined-motor-imagery-and-vestibular-rehab-for-ms-100610625","NCT07230015","Combined Motor Imagery and Vestibular Rehab for MS","The Effectiveness of Combination of Motor Imagery and Vestibular Rehabilitation on Balance, Cognition, and Quality of Life in Patients With Multiple Sclerosis","MIVR-MS","inclusion criteria\n\n1. Diagnosis of Multiple Sclerosis (MS) Confirmed using McDonald Criteria\n2. Patient diagnosed relapsing-remitting multiple sclerosis (RRMS).\n3. Mild MS between 0-3 according to PDDS.\n4. Age from (18-45)\n5. Mild cognitive impairment\n6. Balance impairment (mild to moderate impairment)\n7. Vestibular dysfunction Related to MS (dizziness, vertigo , gaze instability ) 8. Native language is Arabic to ensure clear communication during cognitive tasks and exercise instructions\n\n9\\. Be able to joined the treatment (motor imagery, vestibular rehabilitaiton )\n\nExclusion Criteria:\n\nOther neurological disorder, progressive multiple sclerosis Non-MS related vestibular disorders (e.g., BPPV, Meniere's disease) that would interfere with vestibular rehab.\n\nSevere Psychiatric Conditions (schizophrenia, bipolar, etc) Sever balance disorder Sever fatigue Medical instability eg (cardiovascular disease, respiratory, infections, severe uncontrolled diabetes, or severe visual impairments.) Sever cognitive impairment Pregnant Advance disability ( wheelchair , unable to stand ) Use of Vestibular-Suppressing Medications Non - speaker Arabic","45 Years",{"count":54,"type":22},[25],"This trial investigates the first combined use of motor imagery and vestibular rehabilitation in multiple sclerosis, aiming to evaluate their joint effect on balance, cognition, and quality of life.",[28],[210,211,212,213,214,215,216,217,218,219,220,221,88],"physical therapy","neurological rehabilitation","MS","Vestibular rehabilitation","Motor imagery","balance","QOL","Cognation","randomized control trial","physical therapy modalities","Physical therapy and rehabilitation","physical performance","2026-04-26",{"date":224,"type":35},"2026-04-30",{"date":226,"type":35},"2025-12-01",{"date":228,"type":22},"2026-07-20",{"name":230,"class":42},"Medipol University",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100634915","multicenter-prospective-study-analyzing-the-occurrence-of-multiple-sclerosis-relapses-without-radiological-evidence-myth-or-reality-100634915","NCT07545889","Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?","MYTH-MS","Inclusion Criteria:\n\n* Adult aged 18 to 70 years.\n* Relapsing-Remitting Multiple Sclerosis according to the McDonald 2024 criteria.\n* Patient receiving disease-modifying therapy (DMT) for multiple sclerosis.\n* Most recent EDSS score between 0 and 7.0, dating back less than 1 year.\n* Patient presenting with a neurological exacerbation lasting more than 24 hours and less than 7 days (excluding fatigue and pain alone).\n* Patient capable of understanding the objectives and risks associated with the study and who has provided informed consent.\n* Patient affiliated with or a beneficiary of a social security health insurance scheme.\n\nExclusion Criteria:\n\n* Primary progressive or secondary progressive multiple sclerosis.\n* Diagnosis of chronic psychotic disorder.\n* Infection within the past week.\n* Body temperature \\> 38.5°C at V0 (baseline visit).\n* Corticosteroid bolus or plasma exchange in the month preceding inclusion.\n* Chronic treatment with corticosteroids or immunosuppressants for another pathology.\n* Contraindication to MRI or gadolinium.\n* Uncontrolled cardiac, renal, or hepatic pathology.\n* Patient participating in another interventional study or still within an exclusion period.\n* Pregnant or breastfeeding woman.\n* Severe claustrophobia.\n* Patient deprived of liberty (e.g., incarcerated).","70 Years",{"count":240,"type":22},136,[25],"The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.\n\nWhile MS relapses are typically associated with gadolinium-enhancing lesions on MRI, some patients present with acute neurological symptoms without radiological correlates, referred to as acute clinical events with stable MRI (ACES). The frequency, mechanisms, and clinical relevance of these events remain unclear due to limitations in previous studies.\n\nThe primary objective is to determine the proportion of RRMS patients experiencing a relapse without gadolinium-enhancing lesions on early brain and spinal MRI. Secondary objectives include identifying clinical, radiological, biological, and psychological predictors, assessing neurologists' diagnostic accuracy, and evaluating clinical outcomes such as disability, cognition, and quality of life over a 6-month follow-up.\n\nA total of 136 patients with recent neurological exacerbations will be included. Each participant will undergo clinical assessment, cognitive and psychological evaluation, and early MRI, with follow-up at 6 months. An ancillary study will explore blood biomarkers (NfL, GFAP, and circulating DNA) to help differentiate true inflammatory relapses from ACES.\n\nThis study aims to improve the understanding and diagnosis of MS exacerbations and to optimize patient management by reducing misdiagnosis and unnecessary treatments.",[88,244,28],"RRMS",[88,59,246,247,248,249,250],"Acute Clinical Events with Stable MRI (ACES)","Gadolinium-enhancing lesions","MRI-negative relapse","Functional Neurological Disorder","Pseudo-relapse",{"date":252,"type":35},"2026-04-22",{"date":254,"type":22},"2026-09-01",{"date":256,"type":22},"2030-05-01",{"name":258,"class":42},"University Hospital, Strasbourg, France",8,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":140},"100610267","phase-4-ublituximab-briumvi-for-early-forms-of-relapsing-multiple-sclerosis-100610267","NCT07225361","Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis","Inclusion Criteria:\n\n* Meet 2024 Criteria for Multiple Sclerosis (Montalban et al.) as confirmed by a neurologist; Includes dissemination in space in two of five topographies (with optic nerve included) and\u002For biomarker evidence such as positive cerebrospinal fluid oligoclonal bands, elevated kappa free light chains, at least six central vein lesions, or at least one paramagnetic rim lesion;\n* Adult age 18-70 years,\n* EDSS \\\u003C2.5,\n* Able to provide individual informed consent,\n* MRI brain available to confirm the diagnosis of MS with fewer than 10 demyelinating lesions,\n* Diagnosis of MS within the past \\\u003C5 years,\n* Planning to start Ublituximab for the treatment of relapsing MS,\n\nExclusion Criteria:\n\n* Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,\n* Prior exposure to other B-cell depleting agent including Ocrelizumab, Rituximab, Ofatumumab, and Inebilizumab.\n* Current clinical trial participant,\n* Unable to speak a language for which translation can be found in the hospital system,\n* Unclear documentation of MS diagnosis or prior or current MS treatment,\n* Recent major surgical procedure in the past 6 months,\n* History of life-threatening infusion reaction on Ublituximab or prior anti-CD20 therapy\n* Active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests.\n* Receipt of any live of live-attenuated vaccines within 4 weeks prior to first drug product administration\n* Moribund status,\n* Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, etc.),\n* Unwilling to undergo blood draws,\n* Unable to access Ublituximab through clinical coverage throughout the full 96-week treatment study period,\n* Unable to complete the study activities for any reason as deemed by the study investigator.",{"count":267,"type":22},40,[269],"PHASE4","In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims:\n\n1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \\~12 months.\n2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.",[88,28],[273,274,88,275],"Ublituximab","Briumvi","Relapsing Multiple Sclerosis","2026-03-16",{"date":278,"type":35},"2026-03-17",{"date":280,"type":35},"2025-11-28",{"date":282,"type":22},"2029-08-01",{"name":284,"class":42},"Northwestern University",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":309,"locationsCount":43},"100621911","wearable-focal-vibration-therapy-on-upper-extremity-function-of-people-with-multiple-sclerosis-a-pilot-study-100621911","NCT07376772","Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study","Feasibility, Preliminary Efficacy, and User Perspective Usability of Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study","Inclusion Criteria:\n\n* Aged over 18 years\n* Confirmed diagnosis of RRMS according to the McDonald criteria (33)\n* No MS relapse or exacerbation within the past 6 months (ensuring stability of symptoms)\n* Self-report on clinical evidence of UEx impairment (including reduced arm\u002Fhand function, muscle weakness, spasticity, or pain).\n* Stable on MS treatment for at least four weeks before recruitment, with no plans to initiate new treatments (participants may continue current treatments during the study)\n* Agree and are able to use the FVT device after training.\n* Sufficient proficiency in English to participate in interviews and follow instructions\n* Able to visit the laboratory for assessments\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Evidence of cognitive impairment that could interfere with following instructions (Mini-Montreal Cognitive Assessment score (Mini-MoCA) \\\u003C 12)\n* Comorbid neurological or psychiatric conditions affecting the UEx (including stroke and severe carpal tunnel syndrome) that would confound results or make FVT unsafe\n* Unstable cardiac disease or any major medical illness that would preclude participation\n* Any known contraindications to vibration therapy (pregnancy, acute deep vein thrombosis, severe osteoporosis, chronic migraines, epilepsy, active malignancy in the target area, unstable cardiac disease, or an implanted pacemaker without clearance)","100 Years",{"count":294,"type":22},15,[25],"This pilot mixed-method study will evaluate the feasibility, preliminary efficacy, and user experience of a home-based wearable Focal Vibration Therapy (FVT) intervention for improving upper extremity (UEx) function in people with multiple sclerosis (MS). Fifteen adults with relapsing-remitting MS (PRMS) and self-reported UEx impairments will participate in a 4-week FVT program using MyovoltTM wearable FVT devices applied to arm muscles.",[28,298],"Upper Extremity Dysfunction",[300,127,301,302,303],"focal vibration therapy","upper extremity function","wearable","feasbility","2026-03-04",{"date":306,"type":35},"2026-03-06",{"date":304,"type":35},{"date":135,"type":22},{"name":310,"class":42},"University of Florida",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":43},"100564457","early-phase-1-effects-of-ublituximab-on-motor-functions-in-multiple-sclerosis-100564457","NCT06629428","Effects of Ublituximab on Motor Functions in Multiple Sclerosis","Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People With Relapsing Multiple Sclerosis","U-PACE","Inclusion Criteria:\n\n1. Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments.\n2. Ages between 18 and 55 years old at screening.\n3. Clinically confirmed active, relapsing forms of MS based on the revised McDonald criteria.\n4. Can walk at least 25 feet independently with or without assistive devices at screening.\n5. Can stand independently for at least 30 seconds.\n6. Not pregnant at screening and throughout the study.\n\n   * A negative urine or serum pregnancy test must be available for premenopausal women and for women \\< 12 months after the onset of menopause at screening, unless they have undergone surgical sterilization.\n   * Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use one method of contraception with a failure rate of \\< 1% per year or a barrier method supplemented with spermicide. Contraception must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment.\n\n     * A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of the ovaries and\u002For uterus).\n     * Examples of contraceptive methods with a failure rate of \\< 1% per year include bilateral tube ligation, male sterilization, established hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n     * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence and withdrawal are not acceptable methods of contraception.\n     * Examples of barrier methods supplemented with the use of spermicide include male or female condom, vaginal ring, cap, diaphragm, or sponge.\n7. No other neurological conditions and recent musculoskeletal injuries.\n8. Can read and understand English.\n9. No significant cognitive impairment.\n\nExclusion Criteria:\n\nBasic Exclusion Criteria\n\n1. History of MS types other than relapsing MS at screening (such as primary-progressive MS, inactive SPMS).\n2. History of life-threatening infusion reaction on ublituximab, any of its ingredients, or prior anti-clusters of differentiation 20 (CD20) therapy.\n3. Hypersensitive to any of the ingredients of ublituximab.\n4. Do not understand English.\n\n   Exclusions Related to General Health\n5. Pregnancy or lactation.\n6. Have any other known neurological diseases which may mimic MS, including but not limited to: Neuromyelitis optica, Lyme disease, untreated vitamin B12 deficiency, neurosarcoidosis, and cerebrovascular disorders.\n7. History of clinically significant central nervous system (CNS) trauma (e.g., traumatic brain injury, cerebral contusion, spinal cord compression, etc.).\n8. History of liver disease.\n9. Active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests.\n10. Current evidence or known history of clinically significant infection.\n11. Suffering from coexisting psychiatric disorders, neurological disorders, or severe medical illness.\n12. Current severe depression and\u002For suicidal ideation.\n13. Significant cognitive impairment (Montreal Cognitive Assessment or Montreal Cognitive Assessment (MoCA) score \\< 24).\n14. New onset, unstable orthopedic comorbid diagnoses (within 3 months and uncontrolled).\n15. History or currently active primary or secondary immunodeficiency.\n16. Receipt of a live vaccine within 6 weeks before baseline.\n17. Skin is allergic to transparent double-side tapes.\n18. Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study.\n19. History or currently active primary or secondary immunodeficiency.\n20. Lack of peripheral venous access.\n21. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.\n22. Significant or uncontrolled somatic disease or any other significant disease that may preclude a patient from participating in the study.\n23. Congestive heart failure (NYHA III or IV functional severity).\n24. Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds.\n25. Infection requiring hospitalization or treatment with i.v. antibiotics within four weeks prior to baseline visit or oral antibiotics within two weeks prior to baseline visit.\n26. History or known presence of recurrent or chronic infection (e.g., hepatitis B or C, HIV, syphilis, tuberculosis).\n27. History of progressive multifocal leukoencephalopathy (PML).\n28. History of malignancy, including solid tumors and hematological malignancies, except basal cell carcinoma, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that has been previously completely excised with documented clear margins.\n29. History of alcohol or drug abuse within 24 weeks prior to baseline.\n30. History or laboratory evidence of coagulation disorders.\n\n    Exclusions Related to Medications\n31. Receipt of any live of live-attenuated vaccines within 4 weeks prior to first drug product administration.\n32. Treatment with any investigational agent within 24 weeks of screening (Visit 1) or five half-lives of the investigational drug (whichever is longer).\n33. Systemic corticosteroid therapy within 4 weeks prior to screening.\n34. Any previous treatment with alemtuzumab (Campath), anti-cluster of differentiation 4 (CD4), cladribine, mitoxantrone, daclizumab, tecfidera (BG12), teriflunomide, laquinimod, total body irradiation or bone marrow transplantation.\n35. Treatment with cyclophosphamide, azathioprine, mycophenolate mofetil (MMF), cyclosporine, methotrexate, or natalizumab within 24 months prior to screening.\n36. Treatment with intravenous immunoglobulin within 12 weeks prior to baseline.\n37. Treatment with anti-CD20 or other B cell-directed treatment.\n\n    Exclusions Related to Motor Function\n38. Cannot walk at least 25 feet and stand for at least 30 seconds independently.\n39. Weak or blind vision may impair their ability to walk.\n\n    Exclusions Related to Musculoskeletal, Cardiovascular, and Orthopedic Conditions\n40. Broken bones as an adult in the past year.\n41. Have received neurological treatment, such as Botox, in the past six months.\n42. Heart attack, angioplasty, or coronary artery bypass graft in the past six months.\n43. Congestive heart failure (NYHA III or IV functional severity).\n44. Surgery on back, hip, shoulder, or total joint replacement of hip or knee joint less than two years ago.\n45. Respiratory conditions (lung cancer, bronchitis, emphysema, asthma, shortness of breath) not under regular medical care or the patient is medically unstable.",{"count":320,"type":22},25,[322],"EARLY_PHASE1","The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.",[28],[326,327,328,329,330],"ublituximab","gait function","disease progression","perturbed walking","Cognition","2026-02-05",{"date":333,"type":35},"2026-02-09",{"date":335,"type":35},"2025-11-13",{"date":337,"type":22},"2026-12-31",{"name":339,"class":42},"Georgia State University",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":348,"maxAge":82,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":356,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":140},"100620696","myrosinase-bioactivated-gglucoraphanin-for-the-treatment-of-neurodegenerative-diseases-gra-myr-nd-100620696","NCT07360977","Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)","A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases","GRA-MYR-ND","Inclusion Criteria:\n\nInclusion Criteria for PD:\n\n* Male or female patients aged between 45-75 years old.\n* Clinical diagnosis of PD according to UK Brain Bank Criteria.\n* 3 months of clinical stability before study enrolment.\n* Anti-parkinsonian medication is fixed for at least 3 months prior to study entry.\n\nInclusion Criteria for MS:\n\n* Male or female patients 18 years old or older.\n* Diagnosis of RR-MS according to McDonald criteria.\n* Expanded Disability Status Scale(EDSS) lower or equal to 5.5.\n* Stable disease for at least 30 days prior to study entry.\n* Stable disease-modifying therapy for at least 3 months prior to study entry.\n\nCommon inclusion criteria for MS and PD:\n\n* No changes in drug treatment during 6 months-study treatment.\n* Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project.\n* Written informed consent.\n\nInclusion criteria for pediatric patients:\n\n* Eligible patients are those clinically stable;\n* Age range from 1 to 10, between 5 and 30 kg.\n* Patients not involved in other clinical trials.\n\nExclusion Criteria:\n\nExclusion criteria for PD and MS:\n\n* Absolute contraindications to Magnetic Resonance Imaging (MRI).\n* Concomitant neurological disease or severe co-morbidities able to influence outcomes such as spinal injury, cancer, dementia, or other central nervous system diseases such as stroke, epilepsy or psychiatric disorders;\n* Total score of Mini-Mental State Examination (MMSE)\\\u003C24.\n* Participating in other clinical trials.\n* Pregnant\u002Flactating.","1 Year",{"count":350,"type":22},300,[25],"Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs). ITCs consumption was associated with different health promoting effects, including to neuroprotective, anti-oxidant and anti-inflammatory capacities. In particular, they showed neuroprotective effects in experimental models of neurodegenerative diseases, including multiple sclerosis (MS) and Parkinson's disease (PD). From different GLs, different ITCs are originated. In particular, from glucoraphanin (GRA) the ITC sulforaphane (SFN) is obtained. The PI of the project is one of the proprietor of a patent (EP2908850B1) for the application of (Rs)-GRA with myrosinase in a buffered solution for the treatment of neurodegenerative diseases. The aim of this project is to evaluate the effects of the administration of bioactivated GRA in different cohorts of adult patients, affected by MS and PD, but also a cohort of pediatric patients affected by neuromuscolar and degenerative diseases. The effects of bioactivated (Rs)-GRA administration will be evaluated with a combination of clinical evaluations and a multiomic (metabolomic, genomic) approach.",[354,28,355],"PARKINSON DISEASE (Disorder)","Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases",[357,358,359,360,127],"phytocompounds","Glucosinolates","isothiocyanate","Parkinson's disease","2026-01-14",{"date":363,"type":35},"2026-01-22",{"date":365,"type":22},"2026-01",{"date":131,"type":22},{"name":368,"class":42},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":377,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":140},"100620266","home-based-functional-balance-intervention-for-multiple-sclerosis-100620266","NCT07355387","Home Based Functional Balance Intervention for Multiple Sclerosis","Home Based Functional Balance Intervention (FBI) for Physical and Cognitive Symptoms of Multiple Sclerosis","HomeFBIinMS","Inclusion Criteria\n\nTelephone Screening Inclusion Criteria:\n\n1. Age 40-90 years.\n2. Self-reported diagnosis of Multiple Sclerosis.\n3. On stable disease-modifying therapy for ≥6 months.\n4. No PT\u002FOT balance-related therapy in the past 6 months.\n5. Able to stand from a chair independently (with or without hand support).\n6. Score 25-75% on the 12-item MS Walking Scale.\n7. No other neurological, cardiopulmonary, musculoskeletal, or systemic conditions affecting standing\u002Fwalking.\n8. English speaking.\n9. Willing to complete all study procedures including Zoom sessions.\n10. Has reliable internet access.\n11. Has a helper buddy available for all sessions.\n12. Possible mild cognitive impairment based on self-report.\n\nInitial Screening Inclusion Criteria:\n\n1. Moderate disability: ePR-EDSS score 4.0-6.5.\n2. Mild cognitive impairment: MoCA 18-25, or Jak\u002FBondi criteria for those scoring 26-30.\n3. Physically inactive or moderately active (Godin score \\\u003C24).\n4. Cardiovascular safety parameters within acceptable limits.\n5. No global aphasia (Mississippi Aphasia Screening Test ≥71 percent).\n6. Berg Balance Scale score ≥40\u002F56.\n7. Able to walk 1 block with or without an assistive device.\n\nHelper Buddy Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Lives within close proximity to the participant.\n3. No self-reported major medical conditions limiting safety assistance.\n4. English speaking.\n5. Able to attend all training and assessment sessions.\n6. Able to assist with basic safety, positioning, and communication with the research team.\n7. Has internet access and can use Zoom.\n\nExclusion Criteria\n\nTelephone Screening Exclusion Criteria:\n\n1. MS relapse or exacerbation within the past 3 months.\n2. Recent major surgery (\\\u003C6 months) or hospitalization (\\\u003C3 months).\n3. Resting shortness of breath or uncontrolled pain \\>3\u002F10.\n4. Uncontrolled hypertension or diabetes.\n5. Bone fracture in the past 6 months.\n6. Disability limiting activities of daily living.\n7. History of epilepsy or uncontrolled seizures in past year.\n8. Sedative medication use that may interfere with training.\n9. Use of Alzheimer's\u002Fdementia-modifying drugs or enrollment in AD clinical trials.\n10. Use of antidepressants or anxiety medications.\n11. Moderate or high risk on PAR-Q (≤1 \"yes\" response).\n12. Severe cognitive impairment (TICS-M ≥18).\n13. Currently receiving cognitive or physical rehabilitation.\n14. Pacemaker use.\n\nInitial Screening Exclusion Criteria:\n\n1. Cardiovascular parameters outside safety limits (HR, BP, O₂ saturation).\n2. Global aphasia (Mississippi \\\u003C71 percent).\n3. Peripheral nerve injury.\n4. Berg Balance Scale \\\u003C40\u002F56.\n5. Inability to walk one block with or without an assistive device.\n\nPopulation Exclusions:\n\n1. Non-English speakers (protocol delivered only in English).\n2. Individuals under 18 years.\n3. Pregnant individuals.\n4. Prisoners or other vulnerable populations.","40 Years","90 Years",{"count":380,"type":22},75,[25],"The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS).\n\nCombined Specific Aims:\n\nAim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group).\n\nHypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group.\n\nAim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program.\n\nHypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group.\n\nAim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life).\n\nHypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group.\n\nAll assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy.\n\nThe investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.",[88,28,89,90,384],"Multiple Sclerosis Acute and Progressive",[386,387,88,388,389,390,391,392],"Home based rehabilitation","Telerehabilitation","Mild cognitive impairment","functional balance","safety monitoring","Cognitive motor training","vestibular training","2026-01-12",{"date":395,"type":35},"2026-01-21",{"date":397,"type":35},"2025-11-24",{"date":399,"type":22},"2027-11-24",{"name":401,"class":42},"University of Illinois at Chicago",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":409,"phases":4,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":140},"100610056","selfie-videos-a-novel-patient-centered-comprehensive-approach-to-measuring-function-in-ms-100610056","NCT07222618","\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","Inclusion Criteria:\n\n* Any patient with MS who is above the age of 18 yrs. Participants who are unable to consent for themselves must have a surrogate decision maker or LAR.\n* Age \\> 18 yrs, EDSS - \\\u003C6.5, own a video recording device (smartphone, tablet, camera etc).\n\nExclusion Criteria:\n\n* Patient unwilling to participate in the study. Participants unable to consent for themselves who do not have a surrogate decision maker or LAR.",{"count":350,"type":22},"OBSERVATIONAL","The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired \"selfie\" videos in people with multiple sclerosis. The investigators aim to prove the feasibility and validity of monitoring walking changes remotely through a truly patient-centered, low-burden, low-cost approach. The main question this study aims to answer is: do remotely collected walking and speech videos from a mobile phone match the information investigators can gather from an in person visit?\n\nParticipants will collect 5 \"selfie\" videos at baseline, 3 months, 6 months and 12 months (about 15 minutes every 3 months). They will also come in person at baseline, 6 months, and 12 months for in person data collection (about 1 hour per in person visit).",[88,28,89,412,212,90],"MS (Multiple Sclerosis)",[127,212,414,415],"digital tool","UCSF","2025-10-29",{"date":418,"type":35},"2025-10-31",{"date":420,"type":35},"2025-10-01",{"date":422,"type":22},"2028-10-01",{"name":424,"class":42},"University of California, San Francisco",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":212,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":432,"minAge":433,"maxAge":149,"enrollmentInfo":434,"targetDuration":4,"studyType":409,"phases":4,"briefSummary":436,"conditions":437,"keywords":444,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":140},"100607843","sexual-dysfunction-in-women-with-multiple-sclerosis-ms-100607843","NCT07193823","Sexual Dysfunction in Women With Multiple Sclerosis (MS)","Sexual Dysfunction Prevalence and Its Relationship With Various Factors in Women With Multiple Sclerosis","Inclusion Criteria:\n\n* Female patients aged 25-50 years\n* Literate and able to comprehend written and spoken instructions\n* Diagnosed with relapsing-remitting form of multiple sclerosis\n* Having a continuous\u002Fregular sexual partner\n* Expanded Disability Status Scale (EDSS) score ≤ 5\n* At least 3 months since the last relapse\n* Sexually active within the past 3 months\n* Spasticity level \\\u003C grade 2 according to the Modified Ashworth Scale\n\nExclusion Criteria:\n\n* Pregnancy\n* Illiteracy or inability to understand spoken or written instructions\n* Absence of a continuous\u002Fregular sexual partner\n* Expanded Disability Status Scale (EDSS) score \\> 5\n* Not sexually active within the past 3 months\n* Spasticity level ≥ grade 2 according to the Modified Ashworth Scale","FEMALE","25 Years",{"count":435,"type":22},140,"Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with MS. The secondary objective is to evaluate the relationship between sexual dysfunction and fatigue, depression, anxiety, overactive bladder symptoms, and cognitive dysfunction.\n\nFor this purpose, the following validated instruments will be used: the Female Sexual Function Index (FSFI) to assess sexual dysfunction, the Brief International Cognitive Assessment for MS (BICAMS) to evaluate cognitive function, the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety, the Fatigue Severity Scale (FSS) to measure fatigue, and the Overactive Bladder Questionnaire (OAB-V8) to evaluate overactive bladder symptoms.",[88,28,438,439,440,441,442,443,165],"Fatigue in Multiple Sclerosis","Sexual Disfunction","Cognitive Dysfunction","Depression","Anxiety","Overactive Bladder",[127,445,446,447,448,449,450],"sexual dysfunction","cognitive dysfunction","depression","anxiety","overactive bladder","fatigue","2025-09-22",{"date":453,"type":35},"2025-09-26",{"date":455,"type":35},"2024-07-16",{"date":457,"type":22},"2025-11",{"name":459,"class":42},"Ege University",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":140},"100565368","study-to-investigate-vagus-nerve-stimulation-paired-with-motor-task-for-remyelination-and-functional-recovery-100565368","NCT06641271","Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery","Vagus Nerve Stimulation to Promote Remyelination in Multiple Sclerosis","Inclusion Criteria:\n\n* All participants ages 18-65 with diagnosis of multiple sclerosis at least 30 days from last relapse\n* Baseline grooved peg test time greater than or equal to 108 seconds for completion of the task (1 standard deviation below mean multiple sclerosis score).\n* Ability to sign informed consent\n* expanded disability status scale score (or estimated) of 2.5 or greater OR a clinical report of upper extremity dysfunction in their dominant hand\n\nExclusion Criteria:\n\n* Current uncontrolled and\u002For clinically significant medical condition.\n* Primary progressive multiple sclerosis.\n* History of seizures or epilepsy.\n* Other central nervous system disease or significant brain trauma.\n* Bacterial or viral infection within the prior 30 days.\n* Prior treatment with total body irradiation, clemastine, bexarotene, or other experimental remyelinating agent.\n* Recent suicide attempt or continued expressed suicidal ideation.\n* Implanted devices, such as pacemakers, cochlear prosthesis, neuro-stimulators.\n* Abnormal ear anatomy or ear infection.\n* Pregnancy, lactation, or lack of use of contraception.\n* Unable to walk 25 feet continuously\n* Other significant disease or disorder that might impair study participation. Participants will be allowed to initiate or maintain background disease modifying therapy to reduce the risk of multiple sclerosis relapse and optimize recruitment.",{"count":468,"type":22},70,[25],"The goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function. The main questions it aims to answer are:\n\n* Is stimulating the vagus nerve safe and feasible after demyelinating episodes?\n* Does a paired motor task with vagus nerve stimulation improve motor function with someone who has multiple sclerosis?\n\nResearchers will compare active vagus nerve stimulation to a sham stimulation to see if the paired vagus nerve stimulation can improve motor control.\n\nParticipants will:\n\n* Come in for study visits over a six month period. Study visits are three times weekly for the first month, then single follow up visits at two, three, and six months.\n* During study visits, participants will complete 30 minutes of the paired vagus nerve stimulation with a motor task, specifically the grooved peg test.\n* At various timepoints in the study, motor and disability tests will be administered to see if there are any changes in motor control for that participants. These tests include the timed 25 foot walk test, expanded disability scale, the upper extremity portion of the Fugl-Meyer Assessment, and the Multiple Sclerosis Impact Scale - 29.",[28,88],"2025-03-13",{"date":474,"type":35},"2025-03-14",{"date":476,"type":35},"2025-01-21",{"date":478,"type":22},"2027-11",{"name":480,"class":42},"University of Colorado, Denver",{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":487,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":488,"targetDuration":4,"studyType":409,"phases":4,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":140},"100563062","deuterium-metabolic-imaging-in-people-with-multiple-sclerosis-100563062","NCT06611280","Deuterium Metabolic Imaging in People with Multiple Sclerosis","Inclusion Criteria:\n\n* Aged 18-60 years.\n* Definite Relapsing remitting multiple sclerosis diagnosis according to the most recent diagnostic criteria\n\nExclusion Criteria:\n\n* Contraindications for MRI:\n\nPacemaker, neurostimulator or cholera implant. Metal foreign bodies such as fragments and irremovable piercings. Unsafe medical implants (safety of heart valves, hips and the like must be confirmed).\n\nClaustrophobia. Largest circumference including arms \\> 160 cm\n\n* Pregnancy\n* Competing neurological, psychiatric, or systemic diseases including diabetes (except prior TIA, unspecific brain MRI findings, hypertension, atherosclerosis and hyperlipidemia\u002Fcholesterolemia which are allowed).\n* Participating in other clinical trials with investigational medical products or drugs.",true,{"count":121,"type":22},"The goal of this case-control study is to investigate glucose brain metabolism in people with multiple sclerosis and age- and sex-matched healthy controls. The main questions it aims to answer are:\n\n* How does brain glucose metabolism in people with multiple sclerosis compare to age- and sex-matched healthy controls?\n* How is the brain glucose metabolism of people with multiple sclerosis associated with disease severity?\n\nParticipants will come in for testing lasting approximately three hours and undergo deuterium metabolic imaging, physical function test, cognitive function test, and answer survey.",[28],"2024-10-07",{"date":493,"type":35},"2024-10-09",{"date":495,"type":35},"2024-10-01",{"date":191,"type":22},{"name":498,"class":42},"University of Aarhus"]